Fermentalg has raised US$51 million
Fermentalg has raised US$51 million. US$16 million were raised from its existing shareholders, Demeter, Emertec, and ACE, and US$35 million from news investors, equity funds BPI France, IRDI, Viveris, and Sofiprotéol.
Fermentalg engages in the R&D and production of microalgae by heterotrophic pathway for health, algofuel and aquaculture.
Oaklins’ team in France advised Fermentlag in its fundraising.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more